LOS ANGELES and HOPKINTON, Mass., Oct. 24, 2011 /PRNewswire/ -- DxTerity Diagnostics, Inc. and Caliper Life Sciences, Inc. (NASDAQ: CALP) announced today that the companies have entered into a co-development and co-marketing strategic collaboration that will allow researchers to perform DxTerity's NEAT multiplex diagnostic assays on Caliper's LabChip Dx instrument platform minimizing sample processing time without compromising data quality. Caliper's future LabChip Dx instruments will include specific diagnostic identification, scoring and reporting software, developed in collaboration with DxTerity.
"We are excited to partner with Caliper. The LabChip Dx platform allows DxTerity's customers to directly analyze NEAT assays in minutes at a very low cost per assay. This is coupled with user friendly software and affordable instrument pricing," said Dr. Bob Terbrueggen, President and CEO of DxTerity Diagnostics. "DxTerity's simple and robust NEAT assays, combined with the ease-of-use of the Caliper LabChip Dx system, will eliminate significant barriers to the use of multiplex genomic tests in the clinical laboratory and lead to major gains in personalized medicine."
DxTerity's NEAT assays allow analysis of gene expression and detection of single nucleotide polymorphisms (SNPs) directly from blood or formalin-fixed paraffin embedded (FFPE) tissue samples, virtually eliminating complex sample preparation processes. Multiplex assays for up to 40 gene targets are routinely performed, delivering unique applications for clinical diagnostics and life science research. DxTerity's lead clinical product in development is a blood screening test that measures a patient's radiation exposure following a nuclear event, such as the recent disaster in Fukushima, Japan. The initial release of this p
|SOURCE Caliper Life Sciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved